Compare CLOV & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | TMDX |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2020 | 2019 |
| Metric | CLOV | TMDX |
|---|---|---|
| Price | $5.01 | $92.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $5.60 | ★ $104.55 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.03 | ★ 382.18 |
| EPS | 0.11 | ★ 1.08 |
| Revenue | ★ $1,924,308,000.00 | $605,494,000.00 |
| Revenue This Year | $55.33 | $26.63 |
| Revenue Next Year | $22.64 | $17.56 |
| P/E Ratio | ★ $44.68 | $84.63 |
| Revenue Growth | ★ 40.34 | 37.13 |
| 52 Week Low | $1.58 | $60.11 |
| 52 Week High | $5.59 | $156.00 |
| Indicator | CLOV | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 67.07 |
| Support Level | $4.17 | $65.51 |
| Resistance Level | $5.09 | $92.93 |
| Average True Range (ATR) | 0.28 | 4.70 |
| MACD | 0.04 | 3.29 |
| Stochastic Oscillator | 75.12 | 83.32 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.